Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-lactamase Inhibitor Enmetazobactam.

Belley A, Huband MD, Fedler KA, Watters AA, Flamm RK, Shapiro S, Knechtle P.

J Clin Microbiol. 2019 Jun 5. pii: JCM.00607-19. doi: 10.1128/JCM.00607-19. [Epub ahead of print]

PMID:
31167844
2.

Anodal Transcranial Direct-Current Stimulation to Enhance Rehabilitation in Individuals With Rotator Cuff Tendinopathy: A Triple-Blind Randomized Controlled Trial.

Belley AF, Mercier C, Bastien M, Léonard G, Gaudreault N, Roy JS.

J Orthop Sports Phys Ther. 2018 Jul;48(7):541-551. doi: 10.2519/jospt.2018.7871. Epub 2018 May 10.

PMID:
29747540
3.
4.

[Co-construction of a program to promote community participation among seniors living with psychosocial issues, with or without mental health problems].

Parisien M, Nour K, Belley AM, Aubin G, Billette V, Dallaire B.

Sante Ment Que. Spring 2017;42(1):183-204. French.

PMID:
28792568
5.

Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection.

Belley A, Lalonde-Séguin D, Arhin FF, Moeck G.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01265-17. doi: 10.1128/AAC.01265-17. Print 2017 Oct.

6.

In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.

Arhin FF, Seguin DL, Belley A, Moeck G.

Diagn Microbiol Infect Dis. 2017 Oct;89(2):168-171. doi: 10.1016/j.diagmicrobio.2017.06.023. Epub 2017 Jul 1.

PMID:
28733126
7.

Shoulder proprioception: How is it measured and is it reliable? A systematic review.

Ager AL, Roy JS, Roos M, Belley AF, Cools A, Hébert LJ.

J Hand Ther. 2017 Apr - Jun;30(2):221-231. doi: 10.1016/j.jht.2017.05.003. Review.

PMID:
28641738
8.

Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.

Belley A, Robson R, Francis JL, Adcock DM, Tiefenbacher S, Rubino CM, Moeck G, Sylvester D, Dudley MN, Loutit J.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01968-16. doi: 10.1128/AAC.01968-16. Print 2017 Feb.

9.

Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Sweeney D, Shinabarger DL, Arhin FF, Belley A, Moeck G, Pillar CM.

Diagn Microbiol Infect Dis. 2017 Feb;87(2):121-128. doi: 10.1016/j.diagmicrobio.2016.11.002. Epub 2016 Nov 12.

PMID:
27890418
10.

Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci.

Sweeney D, Stoneburner A, Shinabarger DL, Arhin FF, Belley A, Moeck G, Pillar CM.

J Antimicrob Chemother. 2017 Feb;72(2):622-624. doi: 10.1093/jac/dkw451. Epub 2016 Nov 17. No abstract available.

PMID:
27856721
11.

Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.

Belley A, Lalonde Seguin D, Arhin F, Moeck G.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4342-5. doi: 10.1128/AAC.00169-16. Print 2016 Jul.

12.

[An ecological perspective on the determinants of the cognitive vitality of seniors].

Belley AM, Parisien M, Nour K, Bier N, Ferland G, Guay D, Popov P, Laforest S.

Can J Aging. 2013 Sep;32(3):240-9. doi: 10.1017/S0714980813000299. Epub 2013 Aug 13. Review. French.

PMID:
23942266
13.

Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.

Belley A, Arhin FF, Sarmiento I, Deng H, Rose W, Moeck G.

Antimicrob Agents Chemother. 2013 Jan;57(1):205-11. doi: 10.1128/AAC.01428-12. Epub 2012 Oct 22.

14.

Strain-specific differences in the genetic control of two closely related mycobacteria.

Di Pietrantonio T, Hernandez C, Girard M, Verville A, Orlova M, Belley A, Behr MA, Loredo-Osti JC, Schurr E.

PLoS Pathog. 2010 Oct 28;6(10):e1001169. doi: 10.1371/journal.ppat.1001169.

15.

Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.

Belley A, McKay GA, Arhin FF, Sarmiento I, Beaulieu S, Fadhil I, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2010 Dec;54(12):5369-71. doi: 10.1128/AAC.00760-10. Epub 2010 Sep 27.

16.

Assessment of oritavancin serum protein binding across species.

Arhin FF, Belley A, McKay G, Beaulieu S, Sarmiento I, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2010 Aug;54(8):3481-3. doi: 10.1128/AAC.00271-10. Epub 2010 May 24.

17.

Characterization of the in vitro activity of novel lipoglycopeptide antibiotics.

Arhin FF, Belley A, McKay GA, Moeck G.

Curr Protoc Microbiol. 2010 Feb;Chapter 17:Unit17.1. doi: 10.1002/9780471729259.mc1701s16.

PMID:
20131224
18.

Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.

McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T Jr, Moeck G.

J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126. Epub 2009 Apr 15.

PMID:
19369269
19.

Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

Belley A, Neesham-Grenon E, McKay G, Arhin FF, Harris R, Beveridge T, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2009 Mar;53(3):918-25. doi: 10.1128/AAC.00766-08. Epub 2008 Dec 22.

20.

Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.

Belley A, Harris R, Beveridge T, Parr T Jr, Moeck G.

Antimicrob Agents Chemother. 2009 Feb;53(2):800-4. doi: 10.1128/AAC.00603-08. Epub 2008 Nov 24.

21.

Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.

Belley A, Neesham-Grenon E, Arhin FF, McKay GA, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2008 Oct;52(10):3820-2. doi: 10.1128/AAC.00361-08. Epub 2008 Jul 21.

22.

Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Arhin FF, Sarmiento I, Belley A, McKay GA, Draghi DC, Grover P, Sahm DF, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2008 May;52(5):1597-603. doi: 10.1128/AAC.01513-07. Epub 2008 Feb 25.

23.

Competition of bacteriophage polypeptides with native replicase proteins for binding to the DNA sliding clamp reveals a novel mechanism for DNA replication arrest in Staphylococcus aureus.

Belley A, Callejo M, Arhin F, Dehbi M, Fadhil I, Liu J, McKay G, Srikumar R, Bauda P, Bergeron D, Ha N, Dubow M, Gros P, Pelletier J, Moeck G.

Mol Microbiol. 2006 Nov;62(4):1132-43. Epub 2006 Sep 29. Erratum in: Mol Microbiol. 2006 Dec;62(6):1764. Bergeron, Dominique [added].

24.

Triaminotriazine DNA helicase inhibitors with antibacterial activity.

McKay GA, Reddy R, Arhin F, Belley A, Lehoux D, Moeck G, Sarmiento I, Parr TR, Gros P, Pelletier J, Far AR.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1286-90. Epub 2005 Dec 15.

PMID:
16343901
25.

Novel non-nucleobase inhibitors of Staphylococcus aureus DNA polymerase IIIC.

Rose Y, Ciblat S, Reddy R, Belley AC, Dietrich E, Lehoux D, McKay GA, Poirier H, Far AR, Delorme D.

Bioorg Med Chem Lett. 2006 Feb 15;16(4):891-6. Epub 2005 Nov 17.

PMID:
16298129
26.

Impact of methoxymycolic acid production by Mycobacterium bovis BCG vaccines.

Belley A, Alexander D, Di Pietrantonio T, Girard M, Jones J, Schurr E, Liu J, Sherman DR, Behr MA.

Infect Immun. 2004 May;72(5):2803-9.

27.

Identification and characterization of a cyclooxygenase-like enzyme from Entamoeba histolytica.

Dey I, Keller K, Belley A, Chadee K.

Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13561-6. Epub 2003 Oct 29.

28.

Production of prostaglandin E(2) by Entamoeba histolytica via a novel cyclooxygenase.

Belley A, Chadee K.

Arch Med Res. 2000 Jul-Aug;31(4 Suppl):S74-5. No abstract available.

PMID:
11070230
29.

Prostaglandin E(2) stimulates rat and human colonic mucin exocytosis via the EP(4) receptor.

Belley A, Chadee K.

Gastroenterology. 1999 Dec;117(6):1352-62.

PMID:
10579976
30.

Intestinal mucins in colonization and host defense against pathogens.

Belley A, Keller K, Göttke M, Chadee K.

Am J Trop Med Hyg. 1999 Apr;60(4 Suppl):10-5. Review. Erratum in: Am J Trop Med Hyg 1999 Jun;60(6):1062. Göettke M [corrected to Göttke M].

PMID:
10344672
31.

Functional heterogeneity of colonic adenocarcinoma mucins for inhibition of Entamoeba histolytica adherence to target cells.

Göttke MU, Keller K, Belley A, Garcia RM, Hollingsworth MA, Mack DR, Chadee K.

J Eukaryot Microbiol. 1998 Mar-Apr;45(2):17S-23S.

PMID:
9561779
32.

Interaction of LS174T human colon cancer cell mucins with Entamoeba histolytica: an in vitro model for colonic disease.

Belley A, Keller K, Grove J, Chadee K.

Gastroenterology. 1996 Dec;111(6):1484-92.

PMID:
8942726
33.

Nonsteroidal antiinflammatory drugs inhibit cyclooxygenase-2 enzyme activity but not mRNA expression in human macrophages.

Barrios-Rodiles M, Keller K, Belley A, Chadee K.

Biochem Biophys Res Commun. 1996 Aug 23;225(3):896-900.

PMID:
8780708
34.

Eicosanoid production by parasites: from pathogenesis to immunomodulation?

Belley A, Chadee K.

Parasitol Today. 1995 Sep;11(9):327-34.

PMID:
15275314

Supplemental Content

Loading ...
Support Center